Kawasaki, Japan

Takatoshi Ozawa

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 6.3

ph-index = 1

Forward Citations = 9(Granted Patents)


Location History:

  • Tokyo, JP (2013)
  • Kawasaki, JP (2014)

Company Filing History:


Years Active: 2013-2014

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Takatoshi Ozawa: Innovator in Pharmaceutical Development

Introduction

Takatoshi Ozawa is a prominent inventor based in Kawasaki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative medicinal agents. With a total of 2 patents, his work focuses on addressing critical health issues.

Latest Patents

Ozawa's latest patents include a medicinal agent for the prevention and/or treatment of hepatocellular carcinoma. This invention provides a pharmaceutical agent that combines an acyclic retinoid with branched-chain amino acids, offering a new approach to combat this serious form of cancer. Another notable patent is a pyridine-3-carboxyamide derivative, which serves as a novel JAK3 inhibitor. This compound is useful in treating various conditions, including organ transplant rejection, autoimmune diseases, and certain types of cancer.

Career Highlights

Ozawa is currently associated with Kowa Company Limited, where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on therapeutic strategies in medicine.

Collaborations

Throughout his career, Ozawa has collaborated with notable colleagues, including Takahiro Kitamura and Hajime Yamada. These partnerships have contributed to the success of his innovative projects.

Conclusion

Takatoshi Ozawa's contributions to pharmaceutical innovation highlight his commitment to improving health outcomes through research and development. His patents reflect a dedication to addressing complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…